Markets:

Overview

News

Currencies

International

Treasuries

Pfizer (NY:PFE)

26.68 +0.91 (+3.55%)

Streaming Delayed Price Updated: 2:25 PM EST, Feb 4, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Pfizer

< Previous 1 2 3 4 5 6 7 8 9

...

99 100 Next >

These S&P500 stocks are the most active in today's session ↗

Today 14:05 EST

Via Chartmill

Eli Lilly Soared by 39% in 2025, but Here's Another Healthcare Stock to Buy in 2026 ↗

Today 11:40 EST

Eli Lilly is riding the GLP-1 gravy train, while this competitor is struggling to get on board.

Via The Motley Fool

AI Panic Hits Software, PayPal Faceplants, Walmart Joins the $1T Club ↗

Today 3:11 EST

Via Chartmill

Topics Artificial Intelligence

PFE Q4 CY2025 Deep Dive: Obesity Pipeline and Cost Discipline Face Post-COVID Headwinds

Today 0:32 EST

Global pharmaceutical company Pfizer (NYSE:PFE) beat Wall Street’s revenue expectations in Q4 CY2025, but sales fell by 1.2% year on year to $17.56 billion. The company expects the full year’s revenue...

Via StockStory

Topics Intellectual Property

Pfizer Maps Post-Covid Reset With Obesity Trials And Deep Cost Cuts ↗

February 03, 2026

Via Talk Markets

Pfizer Reports Positive Weight-Loss Trial Results, Strong Q4 – So Why Is PFE Stock Falling? ↗

February 03, 2026

Via Stocktwits

Pfizer Inc. (NYSE:PFE) Beats Q4 2025 Estimates but Muted Outlook Tempers Investor Reaction ↗

February 03, 2026

Via Chartmill

Will the Market Crash in 2026? Here's What History Says and What to Do About It ↗

February 03, 2026

Always be prepared.

Via The Motley Fool

Topics Artificial Intelligence Intellectual Property

3 Unprofitable Stocks with Questionable Fundamentals

February 03, 2026

Running at a loss can be a red flag. Many of these businesses face mounting challenges as competition increases and funding becomes harder to secure.

Via StockStory

Topics Electric Vehicles

Bristol-Myers Squibb Earnings: What To Look For From BMY

February 03, 2026

Biopharmaceutical company Bristol Myers Squibb (NYSE:BMY) will be announcing earnings results this Thursday before the bell. Here’s what to expect.

Via StockStory

Why 2026 Could Be the Year Pfizer's Stock Finally Takes Off ↗

February 03, 2026

The company expects to launch more than 20 pivotal late-stage trials this year.

Via The Motley Fool

Explore the S&P500 index on Tuesday and find out which stocks are the most active in today's session. ↗

February 03, 2026

Via Chartmill

Most active stocks in Tuesday's session ↗

February 03, 2026

Via Chartmill

Rigani Press Announces BioCT's Inaugural Book Event Featuring Dr. S. Yin Ho

February 03, 2026

Via PRLog

Topics Artificial Intelligence

Pfizer (PFE) Q4 2025 Earnings Call Transcript ↗

February 03, 2026

Pfizer (PFE) Q4 2025 Earnings Call Transcript

Via The Motley Fool

Topics Earnings

Why Pfizer Stock Dropped Today ↗

February 03, 2026

Is Pfizer stock a buy at under 9x earnings? Yes. It is.

Via The Motley Fool

Topics Earnings

Pfizer's Newly Acquired Drug Shows Weight Loss Of Just Around 13%, Stock Drops ↗

February 03, 2026

Pfizer reported strong mid-stage weight loss trial results for its monthly obesity drug and posted fourth-quarter earnings that beat analyst estimates, signaling progress in its obesity pipeline.

Via Benzinga

Pfizer Dives After Reaffirming Its Modest Outlook And Providing An Obesity Update ↗

February 03, 2026

Pfizer stock tumbled early Tuesday after the drugmaker reaffirmed its modest outlook for 2026 and provided an obesity update.

Via Investor's Business Daily

These S&P500 stocks are moving in today's pre-market session ↗

February 03, 2026

Via Chartmill

Pfizer (NYSE:PFE) Posts Better-Than-Expected Sales In Q4 CY2025

February 03, 2026

Global pharmaceutical company Pfizer (NYSE:PFE) announced better-than-expected revenue in Q4 CY2025, but sales fell by 1.2% year on year to $17.56 billion. The company expects the full year’s revenue...

Via StockStory

Pfizer Reports Solid Full-Year 2025 Results And Reaffirms 2026 Guidance

February 03, 2026

From Pfizer Inc.

Via Business Wire

Pfizer’s Ultra-Long-Acting Injectable GLP-1 RA Shows Robust and Continued Weight Loss with Monthly Dosing in Phase 2b Trial

February 03, 2026

From Pfizer Inc.

Via Business Wire

Pfizer, Merck And 3 Stocks To Watch Heading Into Tuesday ↗

February 03, 2026

U.S. stock futures up, Pfizer, Teradyne, Merck & Co., Palantir, and AMD expected to release earnings reports. Palantir and AMD beat estimates.

Via Benzinga

The Pharma Reckoning: 2026 Earnings Unveil a New Era of 'TrumpRx' Deals and Looming Patent Cliffs

February 02, 2026

As the pharmaceutical industry enters the heart of its Q4 2025 earnings season this February 2, 2026, a clear divide has emerged between the high-flying giants of the metabolic gold rush and those...

Via MarketMinute

Topics Economy Government Intellectual Property

Is Novo Nordisk Stock a Bargain Right Now? ↗

February 02, 2026

Novo Nordisk just introduced a GLP-1 pill, but the company makes more than just weight-loss drugs.

Via The Motley Fool

Sanofi Found In Breach Of UK Pharmaceutical Marketing Code Over Beyfortus Claims ↗

February 02, 2026

UK regulators ruled Sanofi breached industry rules over RSV claims in a newspaper interview, following a complaint from Pfizer about Beyfortus promotion.

Via Benzinga

Large Cap Biopharmaceuticals: A Core Position For A Healthcare Portfolio ↗

February 02, 2026

Large-cap biopharma offers stable growth and dividends, outperforming the S&P 500 in early 2026. With Gilead up 46% and Pfizer yielding 6%, the sector remains a key volatility hedge following...

Via Talk Markets

Topics Stocks

Option Volatility And Earnings Report For February 2 - 6

February 02, 2026

Last week we saw a plethora of important earnings results and increased market volatility. This wee should be another busy one with a lot of important companies due to report.

Via Barchart.com

3 Headwinds Facing Pfizer in 2026 ↗

February 02, 2026

Pfizer's stock has risen off its lows, but remains 50% below its 2021 highs.

Via The Motley Fool

Topics Intellectual Property

Pfizer Likely To Report Lower Q4 Earnings; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call ↗

February 02, 2026

Via Benzinga

< Previous 1 2 3 4 5 6 7 8 9

...

99 100 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.